Prostate

Papers
(The TQCC of Prostate is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
54
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level38
Erratum to “Inhibition of Signaling Downstream of Beta‐2 Adrenoceptor by Propranolol in Prostate Cancer Cells”31
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente28
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review27
Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study26
Comments on the Study “Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration‐Sensitive Prostate Cancer”26
Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer26
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer23
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy23
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach21
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer21
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity20
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy20
20
A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening20
3βHSD activity saturates at physiological substrate concentrations in intact cells20
19
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis19
Metabolomic Insights Into Saliva as a Non‐Invasive Surrogate for Serum to Enable Community‐Based Biomarker Investigation18
Issue Information18
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study18
A Comparative Study of the Global Burden of Prostate Cancer (1990–2021): Emphasis on the Disparities Between the United States and China18
Strong PD‐L1 expression in granulomatous prostatitis18
Analysis of three primary prostatic sarcoma cases and literature review17
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide17
Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study17
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double‐blind, randomized controlled trial16
Comments on the Study “Evaluating the Efficacy of Barley Water in Alleviating Radiotherapy‐Induced Dysuria in Prostate Cancer Patients”16
16
EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells15
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer15
Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate15
Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer15
The Pubovesical Complex–Sparing Laparoscopic Radical Prostatectomy Improves Early Urinary Continence Without Compromising Oncologic Safety: A Prospective, Randomized, and Double‐Blinded Clinical Trial15
The 28th Annual Prostate Cancer Foundation Scientific Retreat report15
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer15
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide15
Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer15
Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperp15
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score15
Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer15
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients14
14
Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US‐based insurance claims database14
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F‐DCFPyL test–retest cohort14
Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis14
Issue Information14
Detection of intraductal carcinoma in prostate cancer patients with small tumor volume14
The association between beta‐blockers use and prostate cancer mortality: A mini systematic review and meta‐analysis14
Value of synthetic MRI quantitative parameters in preprocedural evaluation for TRUS/MRI fusion‐guided biopsy of the prostate13
Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, c13
13
Issue Information13
Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population13
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining‐targeted biopsy13
Cover Image: Volume 83 Issue 213
Histologic inflammation and collagen content are not positively correlated in human BPH13
Zinc Ameliorates Inflammation and Sperm Parameters in Rats With Experimental Autoimmune Prostatitis13
Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core13
Altered Glycosylation of PSA in Prostate Cancer Tissue13
Emotion‐centered versus fact‐centered medical information to alleviate pain and anxiety in prostate biopsy: A randomized trial13
12
Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model12
Late Bowel Symptoms in Long‐Term Survivors of Prostate Cancer Following Radiotherapy12
Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p‐STAT3 in prostate cancer12
Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways12
Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice12
Pathology of a Canine Model of Localized Prostate Carcinoma12
12
Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing12
12
Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial12
Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume11
Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms11
Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2‐ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE‐UERJ11
Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy11
Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy11
miRNAs Regulating GSTP1 as Potential Diagnostic Biomarkers in Prostate Cancer11
Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy11
Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns11
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations11
Factors impacting on sexual function among men on active surveillance for prostate cancer11
Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers10
Genetics‐Driven, Intensity‐Modulated Adaptive Management of Patients With Metastatic Prostate Cancer10
10
Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide10
Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy10
Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial10
Issue Information10
Erratum to “Differential Impact of Paired Patient‐Derived BPH and Normal Adjacent Stromal Cells on Benign Prostatic Epithelial Cell Growth in 3D Culture”10
Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach10
Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost‐effective?10
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases10
Nomograms for detecting lymph node metastasis detected with surgery—Can you name any birds other than crow?10
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting10
Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score10
Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy10
Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation10
PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer10
Issue Information10
Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparities9
ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era9
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer9
9
Prognostic role of pan‐immune‐inflammation value in patients with metastatic castration‐resistant prostate cancer treated with androgen receptor‐signaling inhibitors9
Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique9
Issue Information9
Role of Volumetric Parameters Derived From Ga‐68 PSMA PET‐CT in Predicting Treatment Response9
Issue Information9
Global Trends in Prostate Cancer Incidence Among Men Aged 55+ (1992–2021): An Age‐Period‐Cohort Analysis9
Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics9
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)9
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate‐Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence9
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer9
Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms9
Prostatic Surgery With Preservation of the Supramonticular Tissue Versus Standard Surgery for Benign Prostatic Hyperplasia: A Systematic Review8
Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity8
8
Epigenetic Regulation of Immune Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome8
8
Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer8
Comparison of Prognosis and Health‐Related Quality of Life Between Robot‐Assisted Radical Prostatectomy Versus High‐Dose‐Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Th8
Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era8
Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI8
Proteoglycans orchestrate remodeling of prostatic cytoarchitecture after androgenic blockade in old gerbils8
Coconut Oil Mitigates the Effects of Aging on the Mongolian Gerbil Prostate8
8
Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk8
Patient‐reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy‐monitored study8
Clinical utility of the prognostic nutritional index in patients with metastatic hormone‐sensitive prostate cancer: A retrospective, multicenter, cohort study8
Issue Information8
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer8
Evaluating the Heterogeneity of Advanced Prostate Cancer by 18F‐DCFPyL and 18F‐FDG PET/CT in a Prospective Cohort8
Polyphyllin I induces ferroptosis in castration‐resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis7
Prostate cancer focal therapy: surgeon experience influences oncological results7
Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation7
Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer7
ATP8B1 : A prognostic prostate cancer biomarker identified via genetic analysis7
A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00)7
Safety and Efficacy of Intra‐Prostatic Injection of Betamethasone for Refractory Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study7
7
Clinical and histopathological parameters in transrectal ultrasound‐guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups7
Head‐to‐head comparison of GA‐68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer7
Diagnosis and management of neuroendocrine prostate cancer7
Issue Information7
Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer7
Issue Information7
Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?7
The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer7
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis7
Evidence and Rationale for Prostate Cancer Screening7
Issue Information7
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients7
Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer7
Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacoth7
Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer7
Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL‐17 signaling pathway gene LCN2 in castration‐resistant prostate cancer7
Mycobacterium Tuberculosis: The Hidden Bacteria in Chronic Prostatitis7
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound7
Issue Information7
Issue Information7
Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis6
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratificatio6
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis6
Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study6
Cover Image: Volume 86 Issue 76
Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and6
Issue Information6
External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients6
Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer6
Risk factors for bladder neck contracture after transurethral resection of the prostate6
Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience6
Chronic coexposure to arsenic and estrogen potentiates genotoxic estrogen metabolic pathway and hypermethylation of DNA glycosylase MBD4 in human prostate epithelial cells6
Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer6
Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study6
Issue Information6
Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists6
6
Issue Information6
Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors6
Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy6
The 30th Annual Prostate Cancer Foundation Scientific Retreat Report6
Discovering the Prostate: Notes on History and Historiography6
USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer6
Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease6
The activated complement pathway in the fibrous process of benign prostatic hyperplasia6
Evaluation of a photodynamic therapy agent using a canine prostate cancer model6
Issue Information6
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate6
Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer5
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer5
Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort5
Evidence for a causal effect of major depressive disorder, anxiety on prostatitis risk: A univariate and multivariate Mendelian randomization study5
Long‐term outcomes of radical prostatectomy versus low‐dose‐rate brachytherapy in patients with intermediate‐risk prostate cancer: Propensity score matched comparison5
Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer5
Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization5
Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro5
IU1 and enzalutamide combination yields synergistic effects on castration‐resistant prostate cancer5
Are higher pre‐diagnosis follicle stimulating hormone levels associated with long‐term prostate cancer risk?5
Other‐cause mortality in incidental prostate cancer5
Significance of extraprostatic extension by Grade Groups 1–3 prostatic carcinoma on needle biopsy5
Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”5
A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide5
Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen depriva5
Correction to “[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign 5
Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer5
Letter to the Editor Regarding “Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization”5
CTPC, a combined transcriptome data set of human prostate cancer cell lines5
Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes5
A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis5
Overall and metastasis‐free survival of Afro‐Caribbean patients with biochemical recurrence after radical prostatectomy5
Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region5
The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer5
Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel5
Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy5
Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors5
Long term update on toxicity and survival of a phase II trial of linac‐based stereotactic body radiation therapy for low‐intermediate risk prostate cancer5
Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy5
Spatial Distribution of Prostate Cancer Missed by MRI‐Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort5
Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study5
Issue Information5
Cover Image: Volume 83 Issue 35
5
Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions5
Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy5
0.039475917816162